- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01235091
Prevention of HIV and STDs in Drug Using Women (WTW)
Women Teaching Women (WTW) is proposed by a team of Washington University investigators who have focused on HIV prevention efforts among out-of-treatment injecting drug users (IDUs) and crack cocaine users, since 1988. Our peer-delivered prevention model was successful in reducing cocaine use among men. The investigators believe no differences were found in drug and sexual risk behaviors for women because the intervention lacked gender-specificity. Thus, the investigators propose to tailor our previous intervention to women's needs to determine the shorter and intermediate term effectiveness of a gender-specific model on reducing drug use and sexual risks. The urgency for women-focused interventions is highlighted by increasing HIV/STD rates among women nationwide. The intervention is designed to bring the HIV prevention message to women in a public health environment. The three-arm intervention, which targets out-of-treatment drug-using women, will assess the differential impact of a woman-centered standard intervention alone, the same standard intervention plus a well-woman exam, and those plus the addition of 4 educational sessions. This proposal responds to two NIDA PAs: 95-083 (Women's HIV Risk and Protective Behaviors) and 96-018 (Drug Abuse Prevention Intervention for Women and Minorities). Our risk reduction, epidemiological and technology transfer aims include:
Risk Reduction Aims:
- Recruit out-of-treatment female drug injectors, heroin, crack/cocaine and methamphetamine users to into an intervention aimed at reducing high risk sexual and drug use behaviors. Street outreach, bars and clubs, shelters, health fairs and daycare facilities will be used to reach these vulnerable women at risk.
- Administer a modified theory-based, peer-delivered, gender and culture-specific intervention that encourages women to reduce their high risk drug and sexual behaviors. Women will be randomly assigned to one of three peer-delivered interventions: a modified NIDA Cooperative Agreement Standard Intervention (SI), the SI + Well-Woman Exam (SI+WWE), or the SI+Well-Woman Exam + 4 Educational Sessions (SI+WWE+4ES). The Standard Intervention will be delivered by peers; the Well-Woman Examination will be conducted by a nurse practitioner; the four 2 hour educational sessions will be conducted by peer facilitators from area drug treatment programs paired with a community mental health or health professional.
- Assess the effectiveness of the interventions in reducing drug and sexual risk at 4 and 12 months post-intervention, controlling for baseline characteristics.
Evaluate the relative cost-effectiveness of each intervention.
Epidemiologic Aim:
Assess: a) incidence of HIV, Hepatitis B and C, syphilis, chlamydia and gonorrhea 12 months post-intervention; b) change in HIV risk and drug and alcohol use at 4 and 12 months post-intervention; c) the effect of psychopathology on behavior change at 12 months post-intervention; d) lifetime history of substance abuse and service utilization for mental and physical problems at baseline.
Technology Transfer Aim:
- Disseminate findings to the scientific community, practitioners and community members in formats that are appropriate, understandable, and usable in order that the best possible women-centered intervention can be developed for reducing HIV risk behaviors. The investigators propose to create a WebSite and present findings at local, national and international symposia. Manuals describing the interventions will be developed and made available to the field.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Over age 18
- Reported sexual activity in the prior 4 months
- Recent cocaine, heroin or amphetamine use
- Reported living in the St. Louis metropolitan area
Exclusion Criteria:
- Under age 18
- No sexual activity in the prior 4 months
- No recent use of cocaine, heroin or amphetamines
- Resides outside the St. Louis metropolitan area
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Standard
NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing
|
At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea.
At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment.
|
|
Experimental: SI/WWE
NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing along with Well-Woman Exam
|
At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea.
At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment.
At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea.
At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment.
This group was assigned to additionally receive a well-woman examination within seven days.
|
|
Experimental: SI/WWE/PD
NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing along with Well-Woman Exam and Peer-delivered Enhanced Intervention
|
At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea.
At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment.
At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea.
At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment.
This group was assigned to receive a well-woman exam within seven days along with four two-hour peer-delivered educational sessions, covering health and nutrition, stress and coping, substance abuse, and HIV/AIDS.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Linda B. Cottler, PhD, MPH, Washington University School of Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 97-0438
- R01DA011622 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sexually Transmitted Diseases
-
Columbia UniversityNational Institute of Allergy and Infectious Diseases (NIAID)CompletedSTI | Sexually Transmitted Disease (STD) | Sexually Transmitted Infection (STI)United States
-
National Institute of Allergy and Infectious Diseases...Terminated
-
Boston Medical CenterCompletedSexually Transmitted InfectionUnited States
-
University of ChicagoCompletedSexually Transmitted InfectionUnited States
-
University of California, San FranciscoNational Institute of Mental Health (NIMH); MRC/UVRI and LSHTM Uganda Research... and other collaboratorsCompletedSexually Transmitted InfectionUganda
-
Boston Medical CenterCompletedSexually Transmitted InfectionUnited States
-
Assistance Publique Hopitaux De MarseilleCompletedSexually Transmitted InfectionFrance
-
Sagami Rubber Industries Co., Ltd.Essential Access HealthCompletedContraception | Prevention of Sexually Transmitted InfectionsUnited States
-
NYU Langone HealthCompletedHiv | Sexually Transmitted InfectionUnited States
-
Centre Hospitalier Régional d'OrléansCompleted
Clinical Trials on NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing
-
University of PennsylvaniaNational Institute of Mental Health (NIMH)CompletedHIV Infections | Sexually Transmitted DiseasesUnited States
-
Susan M. KieneNational Institute of Mental Health (NIMH); Rhode Island Hospital; Makerere UniversityCompletedHIV | Sexual BehaviorUganda
-
San Francisco Department of Public HealthCenters for Disease Control and PreventionCompletedHIV Infections | Episodic Substance UseUnited States